OM
AVTX icon

Opaleye Management’s Avalo Therapeutics AVTX Stock Holding History

Opaleye Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-156
Closed -$225K – 43
2022
Q2 		$225K Sell
156
-349
-69% -$467K 0.1% 44
2022
Q1 		$1.05M Sell
505
-2
-0.4% -$5.02K 0.33% 40
2021
Q4 		$2.48M Hold
507
– – 0.53% 35
2021
Q3 		$3.18M Sell
507
-37
-7% -$300K 0.59% 34
2021
Q2 		$5.13M Sell
544
-359
-40% -$3.01M 0.85% 32
2021
Q1 		$7.85M Sell
903
-7
-0.8% -$66.1K 1.15% 26
2020
Q4 		$6.92M Sell
910
-261
-22% -$1.81M 0.9% 30
2020
Q3 		$7.68M Hold
1,171
– – 1.5% 27
2020
Q2 		$8.77M Buy
1,171
+406
+53% +$2.95M 1.77% 20
2020
Q1 		$5.46M Buy
765
+4
+0.5% +$42.3K 1.45% 20
2019
Q4 		$11.8M Buy
761
+2
+0.3% +$21.1K 2.32% 18
2019
Q3 		$7.19M Hold
759
– – 2.6% 20
2019
Q2 		$11.2M Sell
759
-40
-5% -$606K 3.41% 10
2019
Q1 		$13.4M Buy
799
+40
+5% +$598K 3.72% 4
2018
Q4 		$6.21M Buy
+759
New +$8.46M 2.32% 14

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Opaleye Management's AVTX Position: Q3 2022 in Review

Opaleye Management sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 156 shares — an estimated $225K sold.

Opaleye Management first reported a position in AVTX in Q4 2018 and held it in 15 quarters. The position peaked at $13.4M in Q1 2019. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Opaleye Management reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Opaleye Management sold 156 Avalo Therapeutics shares in Q3 2022, an estimated $225K.
  • Opaleye Management first reported a position in Avalo Therapeutics in Q4 2018 and held it in 15 quarters.
  • Opaleye Management's Avalo Therapeutics position peaked at $13.4M in Q1 2019.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Opaleye Management's 13F filing for Q3 2022, filed 14 Nov 2022.